TMO
2nd
Thermo Fisher Scientific
$250.84Bn
678.40
+0.70%
+46.83%
Through its Clinical Research business, the company provides integrated clinical development and analytical services covering Phases I through IV of clinical trials for pharmaceutical and biotechnology sponsors.
PFE
2nd
Pfizer
$163.75Bn
28.73
+0.17%
+20.46%
The PC1 segment operates as a contract development and manufacturing organization (CDMO) that provides specialty active pharmaceutical ingredients and manufacturing services to external clients.
TEVA
2nd
Teva Pharmaceutical Industries
$45.31Bn
38.88
-0.77%
+102.71%
The company derives income from contract manufacturing arrangements and the sale of active pharmaceutical ingredients to third parties.
IQV
Iqvia Holdings
$44.55Bn
270.68
+0.35%
+49.78%
IQVIA operates a 'Research & Development Solutions' segment that provides outsourced clinical research and clinical trial related services to biopharmaceutical customers. This matches the description of a Contract Research Organization (CRO) that runs clinical development for drug and device sponsors.
ZTS
2nd
Zoetis
$29.58Bn
71.43
+0.53%
-50.07%
The company derives approximately 1% of its revenue from its Client Supply Services organization, which performs contract manufacturing for third parties.
WST
2nd
West Pharmaceutical Services
$26.45Bn
375.66
+1.40%
+44.31%
The company operates a dedicated Contract Manufactured Products segment that provides design, manufacture, and automated assembly of complex devices for pharmaceutical, diagnostic, and medical device customers using customer-owned components.
LH
2nd
Labcorp Holdings
$25.04Bn
309.57
+0.04%
+9.49%
The Biopharma Laboratory Services segment provides end-to-end drug development support, including early-phase research, safety assessment, and clinical trial enablement for pharmaceutical and biotechnology companies. These fee-for-service outsourcing contracts for drug sponsors are the hallmark of Contract Research.
GH
2nd
Guardant Health
$23.69Bn
177.33
+0.05%
+186.06%
The company provides research-focused assays like GuardantINFINITY and GuardantOMNI to biopharmaceutical companies to support clinical trial matching and drug development.
IFF
2nd
International Flavors & Fragrances
$21.89Bn
85.75
+0.09%
+40.67%
The Health & Biosciences segment produces biotechnology-derived enzymes, probiotics, and specialty ingredients sold to the pharmaceutical and health industries. These are functional ingredients manufactured for use in other companies' finished medical or health products.
VTRS
2nd
Viatris
$20.98Bn
18.27
+2.47%
+89.92%
Viatris earns income from contract manufacturing and supply agreements that provide services to third parties by leveraging its own production network.
STE
2nd
Steris
$20.58Bn
211.03
+1.01%
-14.00%
Through its AST segment, the company provides contract sterilization services for medical device and pharmaceutical manufacturers, acting as a contract manufacturer for the sterilization phase of production.
MEDP
Medpace Holdings
$17.19Bn
615.94
-0.48%
+23.00%
Medpace is a global contract research organization (CRO) that provides outsourced clinical development services, including study design, site management, patient recruitment, and regulatory submissions. It earns fee-for-service revenue from biotechnology, pharmaceutical, and medical device sponsors for Phase I through IV clinical trials.
LDOS
2nd
Leidos Holdings
$15.36Bn
122.38
-1.02%
-34.07%
The company provides clinical trials management and research and development support to the National Institutes of Health and the Army Medical Research community.
TEM
2nd
Tempus AI
$14.91Bn
85.08
+0.08%
+8.29%
Tempus generates revenue from contracts for clinical trial matching and other research services provided to pharmaceutical and biotechnology companies.
CRL
Charles River Laboratories International
$14.06Bn
294.68
+0.51%
+100.48%
The company is a leading provider of non-clinical drug development services, specifically offering outsourced drug discovery, target identification, lead optimization, and regulated safety assessment services like toxicology and pathology. These activities are performed for pharmaceutical and biotechnology sponsors as fee-for-service contracts.
ICLR
Icon
$13.44Bn
175.57
+1.88%
+7.42%
ICON is explicitly described as a leading global contract research organization (CRO) that provides outsourced development services, including trial design, execution, and management of Phase I-IV clinical studies for pharmaceutical and biotechnology sponsors.
DVA
2nd
Davita
$11.39Bn
178.03
-0.24%
+36.33%
The company operates a clinical research organization that earns revenue from study sponsorship fees by providing retrospective and prospective studies for drug and device development.
TWST
2nd
Twist Bioscience
$11.26Bn
179.60
-1.77%
+565.19%
The company's Biopharma Services segment provides antibody discovery and optimization services, including high-throughput screening and developability assays, under partnership agreements with pharmaceutical and biotechnology companies.
RDY
2nd
Dr Reddys Laboratories
$10.44Bn
12.51
+2.04%
-10.45%
The Pharmaceutical Services and Active Ingredients (PSAI) segment provides contract manufacturing services and active pharmaceutical ingredients (APIs) to external clients, including other generic drug manufacturers.
PODD
2nd
Insulet
$9.23Bn
133.11
-2.22%
-57.15%
The company manufactures insulin delivery pods for Amgen to be used in the Neulasta Onpro kit under a specific supply agreement, acting as a contract manufacturer for another company's product.
CAI
2nd
Caris Life Sciences
$8.97Bn
31.75
-0.72%
+5.83%
Through its 'Caris Discovery' segment, the company enters into collaborative research and development arrangements with biopharma firms like Moderna and AbbVie to identify novel drug targets and develop therapeutics.
IONS
2nd
Ionis Pharmaceuticals
$7.55Bn
45.57
+2.40%
-28.96%
The company earns revenue from providing manufacturing services to partners for both clinical trial and commercial supply of their therapeutic molecules.
ALKS
2nd
Alkermes
$6.73Bn
40.15
-1.71%
+38.26%
The company earns manufacturing revenues through collaborations with Janssen and Biogen for the production of microspheres and drug substance, acting as a contract manufacturer for these third parties.
LQDA
2nd
Liquidia
$6.56Bn
73.67
+7.66%
+223.11%
The profile explicitly states that Liquidia may earn income from contract manufacturing services for third parties that utilize its proprietary PRINT particle engineering platform.
LNTH
2nd
Lantheus Holdings
$6.51Bn
99.74
+0.00%
+97.04%
The company provides contract development and manufacturing organization (CDMO) services to external partners through its Evergreen subsidiary.
LGND
2nd
Ligand Pharmaceuticals
$6.26Bn
314.10
+4.17%
+81.42%
The company engages in contract manufacturing by selling cGMP manufactured aqueous concentrate and solid Captisol powder to partners such as Gilead, Amgen, and Baxter for use in their pharmaceutical products.
GRFS
2nd
Grifols
$5.04Bn
7.41
+0.82%
-25.38%
The company provides contract manufacturing services to external clients, specifically offering sterile filling, lyophilization, and packaging services.
ADPT
2nd
Adaptive Biotechnologies
$4.53Bn
28.51
-3.13%
+111.81%
The company provides immune receptor sequencing services and target discovery capabilities to biopharmaceutical partners to accelerate therapeutic research in oncology and autoimmune diseases.
ABCL
2nd
AbCellera Biologics
$4.27Bn
13.92
+9.61%
+185.83%
The company provides antibody discovery and development services to pharmaceutical and biotechnology partners, acting as a contract research provider for identifying and optimizing antibodies against challenging targets.
TLX
2nd
Telix Pharmaceuticals
$3.94Bn
11.62
+1.48%
+17.49%
Through its Telix Manufacturing Solutions (TMS) segment, the company provides contract manufacturing services and radiopharmaceutical production capabilities to third-party partners.
OGN
2nd
Organon
$3.61Bn
13.73
+0.00%
+32.66%
Organon generates revenue from contract manufacturing fees, specifically mentioning contract manufacturing arrangements with Merck for various products.
NEO
2nd
Neogenomics
$2.47Bn
19.29
-0.21%
+148.26%
The company provides third-party clinical trials and research support services to pharmaceutical sponsors who require oncology-focused biomarker data.
ADMA
2nd
Adma Biologics
$2.28Bn
10.12
+7.89%
-31.16%
The company generates revenue from providing contract manufacturing and laboratory services to external biopharmaceutical clients.
BHC
2nd
Bausch Health Companies
$2.16Bn
5.78
+1.58%
-10.66%
The company explicitly lists revenue coming from contract manufacturing activities as a source of additional income.
MRVI
2nd
Maravai Lifesciences Holdings
$1.98Bn
7.63
+0.39%
+169.61%
The TriLink segment provides mRNA manufacturing services and GMP materials for preclinical, clinical, and commercial applications, acting as a contract manufacturer for other companies' drug and vaccine candidates.
FTRE
Fortrea Holdings
$1.91Bn
20.06
+0.85%
+138.81%
Fortrea is a global contract research organization (CRO) that provides phase I through IV clinical trial management, patient recruitment, and biostatistics for pharmaceutical and medical device sponsors. Its revenue is derived from fee-for-service and full-service outsourcing contracts for clinical research services.
NVAX
2nd
Novavax
$1.78Bn
10.80
+1.60%
+26.02%
The company operates an adjuvant segment that involves the manufacturing of its proprietary Matrix-M™ saponin-based adjuvant at its facility in Uppsala, Sweden, and licenses this manufacturing capability and technology to partners for use in their own vaccine programs.
SCNI
2nd
Scinai Immunotherapeutics
$1.37Bn
1.47
-5.16%
-87.75%
The company operates a CDMO business through Scinai Biopharma Services Ltd., providing cGMP manufacturing for biologics and small molecules, as well as fill-and-finish operations for external biopharmaceutical clients.
IART
2nd
Integra Lifesciences Holdings
$1.27Bn
16.27
+0.93%
+19.37%
The Tissue Technologies segment provides private label and contract manufacturing services for other medical technology companies seeking custom biomaterial solutions.
AMPH
2nd
Amphastar Pharmaceuticals
$1.16Bn
27.39
+4.82%
+1.75%
The company manufactures and sells active pharmaceutical ingredient (API) products, such as recombinant human insulin and porcine insulin API, to third parties.
MGTX
2nd
MeiraGTx Holdings
$1.05Bn
11.11
+1.83%
+34.67%
The company operates internal GMP facilities for viral vector and plasmid production and generates revenue from manufacturing services under supply agreements, specifically citing a commitment to produce gene therapy products for Johnson & Johnson Innovative Medicine.
LXRX
2nd
Lexicon Pharmaceuticals
$849.05Mn
1.90
+6.15%
+36.69%
The company's profile explicitly states that it may receive income from contract manufacturing services in addition to its own product sales.
AVR
2nd
Anteris Technologies Global
$753.96Mn
7.74
+0.65%
+77.52%
The company operates a business line supplying its proprietary ADAPT® anti-calcification tissue to third parties, such as 4C Medical Technologies, under licensing and supply agreements.
QDEL
2nd
QuidelOrtho
$739.69Mn
10.83
-1.01%
-62.50%
The company explicitly earns revenue from contract manufacturing services in addition to its own branded diagnostic product sales.
OABI
2nd
OmniAb
$689.15Mn
4.74
+2.82%
+194.41%
The company generates service revenue by performing research services for partners, including specific programs focused on small molecule ion channels.
STLN
2nd
Starling Oncology
$667.11Mn
6.64
-0.30%
+91.91%
The company manages clinical trial programs and bills pharmaceutical companies or contract research organizations for procedures performed on enrolled patients.
DNA
Ginkgo Bioworks Holdings
$665.78Mn
10.45
-1.97%
-21.01%
Ginkgo Bioworks operates as a platform providing R&D services, cell engineering solutions, and high-throughput data generation for external sponsors. Its revenue model is based on service fees, milestone payments, and value-share arrangements for projects involving therapeutics, vaccines, and industrial chemicals for customers like Biogen and Novo Nordisk.
AQST
2nd
Aquestive Therapeutics
$596.18Mn
4.75
+1.50%
-15.93%
The company generates significant revenue by manufacturing and supplying licensed commercial products to pharmaceutical partners, such as Suboxone for Indivior and Emylif for Zambon.
EVO
Evotec SE
$565.34Mn
1.59
+2.58%
-55.08%
Evotec provides integrated drug discovery and preclinical development services, including target identification, lead optimization, and IND enabling programs. The company generates the vast majority of its revenue (79% in 2025 and 94% in 2024) through fee-for-service and FTE-based contracts for pharmaceutical and biotechnology partners.
YDES
2nd
YD Bio
$503.31Mn
7.11
+24.08%
-60.65%
YD Bio generates current revenue from fees received for supplying clinical trial materials and services to pharmaceutical partners, including service agreements with Novartis Taiwan and Alcon Services AG Taiwan Branch.
CLPT
2nd
ClearPoint Neuro
$467.00Mn
15.31
+3.24%
-29.02%
The company provides preclinical development services, including protocol consultation, study design, and in vivo biology testing for pharmaceutical and biotechnology partners. These services are sold to over 60 partners to support the development of gene and cell therapies.
RGNX
2nd
Regenxbio
$404.61Mn
7.47
+0.95%
-24.16%
The company provides a scalable manufacturing and development platform, specifically the NAVXpress manufacturing process, to support its own pipeline and collaborations with partners.
WDH
2nd
Waterdrop
$371.71Mn
1.03
-1.90%
-46.63%
The company provides the E-Find patient recruitment service, charging pharmaceutical and biotechnology clients a fixed fee for matching and enrolling suitable participants in clinical trials.
EBS
2nd
Emergent BioSolutions
$352.43Mn
6.87
+1.03%
-23.15%
The company operates a Services Segment that provides drug substance and drug product manufacturing, fill-finish, and packaging services to external biopharmaceutical companies and government agencies.
EMBC
2nd
Embecta
$335.99Mn
5.93
+0.51%
-57.64%
The company explicitly earns contract manufacturing revenue from third-party arrangements, indicating it manufactures medical products on behalf of other sponsors.
BDSX
2nd
Biodesix
$320.93Mn
30.42
+4.54%
+293.02%
The company's Development Services segment provides end-to-end solutions including translational research, biomarker discovery, and testing of clinical trial samples for biopharmaceutical and life sciences clients. This activity constitutes a fee-for-service contract research model for drug and device sponsors.
EYPT
2nd
EyePoint
$281.29Mn
3.31
-8.56%
-76.44%
The company operates a commercial manufacturing facility in Northbridge, Massachusetts, and generates revenue by manufacturing and supplying certain products to its partners.
OSUR
2nd
Orasure Technologies
$278.04Mn
3.95
+0.51%
+24.21%
The company explicitly generates income from contract manufacturing services for third parties who require its proprietary collection devices.
IMRX
2nd
Immuneering
$269.14Mn
4.16
-2.58%
-38.37%
The company generates current revenue by providing translational bioinformatics analyses and tumor modeling services for pharmaceutical and biotechnology partners such as Johnson & Johnson and Bristol Myers Squibb.
STRO
2nd
Sutro Biopharma
$265.72Mn
16.03
+0.31%
+82.16%
The company provides manufacturing support to its partners using its proprietary XpressCF and XpressCF+ platforms, which allow for scalable manufacturing of proteins without cell lines.
MGNX
2nd
Macrogenics
$258.40Mn
4.06
+8.56%
+132.00%
The company operates a commercial-scale cGMP manufacturing facility and provides contract development and manufacturing services to third parties and collaborators such as Incyte and Emergent BioSolutions.
LFCR
Lifecore Biomedical
$241.41Mn
6.52
+55.24%
-8.81%
Lifecore is a contract development and manufacturing organization (CDMO) that provides cGMP manufacturing and aseptic filling of sterile injectable pharmaceutical products for biopharmaceutical and biotechnology customers. Its revenue is derived from development fees, technology transfer, and manufacturing services for others' drug products.
AGPU
2nd
Axe Compute
$239.18Mn
12.15
+0.50%
-32.50%
The company provides AI-driven drug response predictions and three-dimensional tumor model services to biopharma partners and contract research organizations to support oncology R&D.
UTMD
2nd
Utah Medical Products
$237.10Mn
74.49
+0.42%
+18.77%
The company earns income by manufacturing components and finished devices on a subcontract basis for other medical device and non-medical device firms, including OEM customers like PendoTECH.
XGN
2nd
Exagen
$205.16Mn
8.48
-2.75%
-21.26%
The company generates revenue from agreements with pharmaceutical companies and contract research organizations (CROs) for the use of its testing products and the provision of de-identified data for research and development purposes.
BNR
2nd
Burning Rock Biotech
$185.44Mn
17.63
-5.22%
+87.75%
The company generates revenue from collaborations with pharmaceutical companies, such as AstraZeneca and Bayer, specifically for clinical trial support and the development of companion diagnostics.
KRMD
2nd
KORU Medical Systems
$141.21Mn
3.06
-4.67%
-20.31%
The company generates revenue from a 'Pharma services and clinical trials' segment, providing feasibility and early-stage trial support to biopharmaceutical firms developing new subcutaneous therapies.
CDXS
2nd
Codexis
$124.29Mn
1.36
+3.03%
-44.94%
The company provides contract development and manufacturing services through its ECO synthesis manufacturing platform, specifically for the large-scale manufacture of RNA interference therapeutics.
MXCT
2nd
Maxcyte
$123.12Mn
1.16
-0.85%
-22.67%
Through its acquisition of SeQure Dx, the company provides gene-editing risk assessment services, including GUIDE-seq and ONE-seq assays, to help developers evaluate on-target and off-target editing outcomes for regulatory submissions.
APYX
2nd
Apyx Medical
$105.29Mn
2.50
-15.54%
+14.68%
The company operates an OEM segment where it designs and manufactures electrosurgical generators and accessories for other medical device manufacturers, such as Symmetry Surgical, under long-term supply agreements.
IMDX
2nd
Insight Molecular Diagnostics
$103.74Mn
3.18
-18.88%
-1.55%
The company earns fees by providing laboratory services to life sciences and biotechnology companies specifically for assay development and clinical testing.
NTRB
2nd
NutriBand
$100.04Mn
8.23
+2.87%
+16.57%
Through its subsidiary Pocono Pharmaceuticals (operating as Active Intelligence), the company provides contract manufacturing, including formulation, blending, filling, and packaging of topical and transdermal products for external health and wellness and OTC pharmaceutical customers.
PTHS
2nd
Pelthos Therapeutics
$81.21Mn
21.84
-2.37%
-27.20%
The company generates income from manufacturing services under a master services agreement with Ligand Pharmaceuticals, which includes supplying active pharmaceutical ingredients (API) using its NITRICIL platform.
CSBR
Champions Oncology
$68.06Mn
4.89
-0.20%
-23.35%
The company's largest revenue contributor is its research services business, which provides preclinical study contracts to pharmaceutical and biotechnology firms using its proprietary TumorBank of Patient Derived Xenograft models. These services include in vivo and ex vivo experiments to measure drug response and resistance, fitting the definition of a contract research organization.
XBIT
2nd
XBiotech
$65.55Mn
2.15
-0.92%
-20.07%
The company operates a manufacturing center and has generated revenue from a manufacturing supply agreement with a world-leading pharmaceutical company.
HYFT
MindWalk Holdings
$62.59Mn
1.34
-2.90%
-22.54%
The company generates 100% of its revenue from contract research organization (CRO) services, providing end-to-end antibody discovery and development for biopharmaceutical companies and academic institutions. Specific services include custom antigen modeling, B cell sorting, phage display library screening, and antibody characterization.
CELU
2nd
Celularity
$40.37Mn
1.40
+1.45%
-34.88%
Celularity earns income by providing contract manufacturing and development services to third-party biopharma firms using its placental-cell expertise and cGMP-compliant facility.
LASE
2nd
Laser Photonics
$34.23Mn
0.87
+1.16%
-77.75%
Through its Pharmaceutical Laser Systems segment, the company provides turnkey laser material processing systems for pharmaceutical manufacturing, specifically for precision micro-drilling used in controlled-release medications.
SCLX
2nd
Scilex Holding
$31.59Mn
4.49
-8.18%
-72.92%
The company explicitly earns revenue from providing contract manufacturing services in addition to its own product sales.
NSYS
2nd
Nortech Systems
$31.11Mn
10.90
-3.63%
+20.71%
Over 50% of net sales are derived from medical related markets, where the company provides contract manufacturing for complex electromedical devices and medical imaging systems for OEMs.
ABVC
2nd
Abvc Biopharma
$27.06Mn
1.05
-7.08%
-65.91%
The company operates a GMP-certified manufacturing facility through its subsidiary BioKey, which provides contract development and manufacturing organization (CDMO) services to third parties.
BHST
2nd
Bioharvest Sciences
$26.70Mn
1.45
-0.68%
-85.44%
The company operates a CDMO Services Business Unit that provides contract development and manufacturing operations for pharmaceutical, cosmeceutical, and nutraceutical clients, managing the process from cell line development to commercial scale production.
COSM
2nd
Cosmos Health
$22.17Mn
0.37
+5.71%
-65.42%
Cosmos Health generates revenue from contract manufacturing for third parties, utilizing its GMP and EMA manufacturing licenses.
DQWS
2nd
DSwiss
$16.55Mn
0.08
+0.00%
+166.67%
DSwiss operates as a turnkey Private Label ODM/OEM provider, offering end-to-end manufacturing and production services for other companies' health and beauty brands.
BFRG
2nd
BullFrog AI Holdings
$12.24Mn
0.66
-1.49%
-52.17%
The company provides fee-for-service contract analysis and data analysis services to biopharmaceutical companies and academic institutions to help identify drug targets and streamline clinical trial design.
NAII
Natural Alternatives International
$10.67Mn
1.70
-3.41%
-41.58%
The company's largest revenue source is private-label contract manufacturing, where it handles the formulation and production of vitamins, minerals, and herbal supplements for third-party companies. It provides a comprehensive suite of services including scientific research, product testing, and regulatory review for these sponsors.
PLUR
2nd
Pluri
$9.96Mn
0.92
-8.91%
-80.04%
The company operates PluriCDMO, a contract development and manufacturing organization that provides cell therapy production services, process development, and analytical support to biotech and pharmaceutical clients.
PBSV
2nd
Pharma-Bio Serv
$8.02Mn
0.35
-20.45%
-46.15%
The company provides validation, regulatory compliance, and process support services to pharmaceutical and biotechnology companies, which are core activities of contract research and development outsourcing for drug and device sponsors.
LGVN
2nd
Longeveron
$7.96Mn
2.63
-6.41%
-65.84%
The company generates revenue by providing contract manufacturing and development services to external biotechnology sponsors, including manufacturing execution, quality control testing, and release certification at its cGMP facility.
GELS
Gelteq
$5.89Mn
0.55
+0.00%
-60.14%
Gelteq operates as a white-label manufacturer and licensor of gel-based delivery solutions for prescription drugs and therapeutics. Its revenue model is based on manufacturing products for third-party clients and receiving milestone fees and licensing payments for its drug delivery technology.
AIDX
2nd
20
$5.02Mn
0.41
-4.65%
—
Through its Clinical Laboratory Innovation Accelerator (CLIAx), the company provides shared laboratory services, equipment, and personnel to diagnostics start-ups to help them validate and launch their tests.
CLGN
2nd
CollPlant Biotechnologies
$4.95Mn
3.87
-8.94%
-87.48%
The company explicitly derives revenue from providing contract manufacturing services and supplying rhCollagen for partner-led product commercialization.
VSBC
2nd
Vitaspring Biomedical
$2.07Mn
0.01
+0.00%
-99.00%
The company expects to generate income by providing contract manufacturing services for stem cell culture, purification, and exosome production to third party laboratories, hospitals, and research organizations.
NXGL
Nexgel
$1.75Mn
0.18
+5.88%
-92.56%
NexGel operates as a contract manufacturer supplying electron beam cross linked hydrogels to third parties for use in drug delivery, medical applications, and wound dressings. Revenue is explicitly derived from the sale of these hydrogels to contract manufacturing customers who incorporate them into their own products.
VIVS
VivoSim Labs
$1.15Mn
0.22
+0.00%
-92.72%
VivoSim Labs operates as a service provider for pharmaceutical and biotech partners, offering liver and intestinal toxicology screening and mechanism-of-action studies. These activities match the description of a contract research organization (CRO) that runs preclinical development and safety testing for drug sponsors.
SKVI
2nd
Skinvisible
$1.08Mn
0.20
+0.00%
-9.09%
Through its Co-Development segment, the company provides formulation expertise and delivery system integration to pharmaceutical clients to help them develop optimal formulations for clinical testing.
CPMV
2nd
Mosaic ImmunoEngineering
$434.53K
0.06
+0.00%
-92.21%
The company generates limited revenue by providing advisory and related services to collaborators, such as the fees earned under its Master Services Agreement with Oncotelic Therapeutics, Inc.
NOTVQ
Inotiv
$348.88K
0.01
+0.00%
—
Inotiv explicitly identifies as a contract research organization (CRO) providing nonclinical and analytical drug discovery and development services. Its Discovery and Safety Assessment (DSA) segment provides bioanalytical method development, in vivo pharmacology, and non-clinical toxicology services to pharmaceutical and medical device sponsors.
CBIH
Cannabis Bioscience International Holdings
$0.00
0.00
—
—
The company operates the Alpha Research Business, which provides clinical trial services including study design, patient recruitment, and data reporting for pharmaceutical and biotech clients such as Pfizer and Novartis.